drugset
drugset / Trial / NCT05308225

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

NCT05308225 ↗

Phase 1/2 Active not recruiting 72 enrolled Sorrento Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.

Timeline

Start
2023-02-01
Primary completion
2025-12
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject STI-6129 Other / unclassified 0.67 mg/kg Intravenous
Subject STI-6129 Other / unclassified 0.88 mg/kg Intravenous
Subject STI-6129 Other / unclassified 1.18 mg/kg Intravenous
Subject STI-6129 Other / unclassified 1.56 mg/kg Intravenous
Subject STI-6129 Other / unclassified 2.08 mg/kg Intravenous
Subject STI-6129 Other / unclassified 2.77 mg/kg Intravenous
Subject STI-6129 Other / unclassified 3.68 mg/kg Intravenous

Indications

plasma cell myeloma